Last updated: 31 July 2018 at 7:51am EST

Douglas K Monoline Partners... Net Worth




The estimated Net Worth of Douglas K Monoline Partners... is at least 817 千$ dollars as of 24 July 2018. Douglas Partners owns over 165,000 units of Aquestive Therapeutics Inc stock worth over 816,750$ and over the last 6 years Douglas sold AQST stock worth over 0$.

Douglas Partners AQST stock SEC Form 4 insiders trading

Douglas has made over 1 trades of the Aquestive Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Douglas bought 165,000 units of AQST stock worth 2,475,000$ on 24 July 2018.

The largest trade Douglas's ever made was buying 165,000 units of Aquestive Therapeutics Inc stock on 24 July 2018 worth over 2,475,000$. On average, Douglas trades about 165,000 units every 0 days since 2018. As of 24 July 2018 Douglas still owns at least 165,000 units of Aquestive Therapeutics Inc stock.

You can see the complete history of Douglas Partners stock trades at the bottom of the page.



What's Douglas Partners's mailing address?

Douglas's mailing address filed with the SEC is 201 Main St, Salinas, CA 93901, USA.

Insiders trading at Aquestive Therapeutics Inc

Over the last 6 years, insiders at Aquestive Therapeutics Inc have traded over 1,898,648$ worth of Aquestive Therapeutics Inc stock and bought 370,463 units worth 3,088,399$ . The most active insiders traders include Marco TagliettiNancy LurkerAlexander Mark Schobel. On average, Aquestive Therapeutics Inc executives and independent directors trade stock every 36 days with the average trade being worth of 77,928$. The most recent stock trade was executed by Alexander Mark Schobel on 15 March 2024, trading 50,000 units of AQST stock currently worth 300,000$.



What does Aquestive Therapeutics Inc do?

aquestive therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people’s lives. our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. our initial focus, supported by our current approved products and late stage pipeline, is to address immediate cns challenges.



Complete history of Douglas Partners stock trades at Aquestive Therapeutics Inc

インサイダー
取引
取引
合計金額
Douglas K Monoline Partners...
購入する 2,475,000$
24 Jul 2018


Aquestive Therapeutics Inc executives and stock owners

Aquestive Therapeutics Inc executives and other stock owners filed with the SEC include: